


Cinnamic acid-¹³C₃

Cat. No.:	HY-N0610AS2	
CAS No.:	2734410-01-4	
Molecular Formula:	C ₆ ¹³ C ₃ H ₈ O ₂	
Molecular Weight:	151.14	
Target:	Endogenous Metabolite; Isotope-Labeled Compounds	
Pathway:	Metabolic Enzyme/Protease; Others	
Storage:	Powder	-20°C 3 years 4°C 2 years
	In solvent	-80°C 6 months -20°C 1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 125 mg/mL (827.05 mM; ultrasonic and warming and heat to 60°C)

Solvent	Mass	Concentration		
		1 mg	5 mg	10 mg
Preparing Stock Solutions	1 mM	6.6164 mL	33.0819 mL	66.1638 mL
	5 mM	1.3233 mL	6.6164 mL	13.2328 mL
	10 mM	0.6616 mL	3.3082 mL	6.6164 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Cinnamic acid-¹³C₃ (3-Phenylacrylic acid-¹³C₃) is the ¹³C labeled Cinnamic acid (HY-N0610A). Cinnamic acid has potential use in cancer intervention, with IC₅₀s of 1-4.5 mM in glioblastoma, melanoma, prostate and lung carcinoma cells^{[1][2]}.

In Vitro

Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has gained attention because of its potential to affect the pharmacokinetic and metabolic profiles of drugs^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. *Ann Pharmacother.* 2019;53(2):211-216.

[2]. Liu L, et al. Cinnamic acid: a natural product with potential use in cancer intervention. *Int J Cancer.* 1995 Jul 28;62(3):345-50.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA